PIM-1 Inhibitor 2Potent Pim-1 kinase inhibitor CAS# 477845-12-8 |
- IPI-145 (INK1197)
Catalog No.:BCC1104
CAS No.:1201438-56-3
- IC-87114
Catalog No.:BCC1161
CAS No.:371242-69-2
- PI-103
Catalog No.:BCC1162
CAS No.:371935-74-9
- PIK-75
Catalog No.:BCC1163
CAS No.:372196-77-5
- TGX-221
Catalog No.:BCC1244
CAS No.:663619-89-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 477845-12-8 | SDF | Download SDF |
PubChem ID | 2765355 | Appearance | Powder |
Formula | C17H11CIN4O | M.Wt | 426.2 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 75 mM in DMSO | ||
Chemical Name | 4-[3-(4-chlorophenyl)-2,1-benzoxazol-5-yl]pyrimidin-2-amine | ||
SMILES | C1=CC(=CC=C1C2=C3C=C(C=CC3=NO2)C4=NC(=NC=C4)N)Cl | ||
Standard InChIKey | AQVFETGXIRKVAQ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C17H11ClN4O/c18-12-4-1-10(2-5-12)16-13-9-11(3-6-15(13)22-23-16)14-7-8-20-17(19)21-14/h1-9H,(H2,19,20,21) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent Pim-1 kinase inhibitor (Ki = 91 nM). |
PIM-1 Inhibitor 2 Dilution Calculator
PIM-1 Inhibitor 2 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3463 mL | 11.7316 mL | 23.4632 mL | 46.9263 mL | 58.6579 mL |
5 mM | 0.4693 mL | 2.3463 mL | 4.6926 mL | 9.3853 mL | 11.7316 mL |
10 mM | 0.2346 mL | 1.1732 mL | 2.3463 mL | 4.6926 mL | 5.8658 mL |
50 mM | 0.0469 mL | 0.2346 mL | 0.4693 mL | 0.9385 mL | 1.1732 mL |
100 mM | 0.0235 mL | 0.1173 mL | 0.2346 mL | 0.4693 mL | 0.5866 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Potent Pim-1 kinase inhibitor (Ki = 91 nM).
- Tofacitinib (CP-690550,Tasocitinib)
Catalog No.:BCC2192
CAS No.:477600-75-2
- PHA-665752
Catalog No.:BCC1181
CAS No.:477575-56-7
- Musellarin A
Catalog No.:BCN7186
CAS No.:477565-36-9
- Sculponeatin K
Catalog No.:BCN5537
CAS No.:477529-70-7
- Ophiopogonanone C
Catalog No.:BCN6620
CAS No.:477336-75-7
- cis-ACPD
Catalog No.:BCC6566
CAS No.:477331-06-9
- (±)-AC 7954 hydrochloride
Catalog No.:BCC7381
CAS No.:477313-09-0
- Mangiferin
Catalog No.:BCN5535
CAS No.:4773-96-0
- Bergenin
Catalog No.:BCN5540
CAS No.:477-90-7
- Digitolutein
Catalog No.:BCN3089
CAS No.:477-86-1
- Obtusifolin
Catalog No.:BCN2537
CAS No.:477-85-0
- Damnacanthal
Catalog No.:BCN5539
CAS No.:477-84-9
- 3-(2-Glucosyloxy-4-methoxyphenyl)propanoic acid
Catalog No.:BCN7068
CAS No.:477873-63-5
- Neostenine
Catalog No.:BCN5541
CAS No.:477953-07-4
- Nobiletin
Catalog No.:BCN5542
CAS No.:478-01-3
- Lucidin
Catalog No.:BCC1709
CAS No.:478-08-0
- Pseudoaspidin
Catalog No.:BCN6386
CAS No.:478-28-4
- Eleutherin
Catalog No.:BCN8475
CAS No.:478-36-4
- Droserone
Catalog No.:BCN7985
CAS No.:478-40-0
- Rhein
Catalog No.:BCN5947
CAS No.:478-43-3
- Berbamine
Catalog No.:BCN5543
CAS No.:478-61-5
- Pseudococaine
Catalog No.:BCN1902
CAS No.:478-73-9
- PHA 543613 hydrochloride
Catalog No.:BCC5972
CAS No.:478149-53-0
- Isoerysenegalensein E
Catalog No.:BCN3978
CAS No.:478158-77-9
Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)- 5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.[Pubmed:26505898]
J Med Chem. 2015 Nov 12;58(21):8373-86.
Pan proviral insertion site of Moloney murine leukemia (PIM) 1, 2, and 3 kinase inhibitors have recently begun to be tested in humans to assess whether pan PIM kinase inhibition may provide benefit to cancer patients. Herein, the synthesis, in vitro activity, in vivo activity in an acute myeloid leukemia xenograft model, and preclinical profile of the potent and selective pan PIM kinase inhibitor compound 8 (PIM447) are described. Starting from the reported aminopiperidyl pan PIM kinase inhibitor compound 3, a strategy to improve the microsomal stability was pursued resulting in the identification of potent aminocyclohexyl pan PIM inhibitors with high metabolic stability. From this aminocyclohexyl series, compound 8 entered the clinic in 2012 in multiple myeloma patients and is currently in several phase 1 trials of cancer patients with hematological malignancies.
Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase.[Pubmed:18290603]
J Med Chem. 2008 Mar 27;51(6):1972-5.
To supplement the hits from a high throughput screen, docking was performed against Pim-1 kinase. Glide docking was augmented with a filter to require traditional or aromatic CH..O hydrogen bonds to the kinase hinge. Four diverse actives, of 96 molecules assayed, had K(i) values between 0.091 and 4.5 microM. This gives a 14-fold enrichment over the earlier HTS run, and the two crystal structures solved confirmed the binding modes predicted by docking.